Shocking Survival Claim Ignites Hospital Power Fight

A Senate roundtable heard a striking claim that 69 of 72 court-ordered ivermectin patients survived, reviving the fight over who controls treatment in America’s hospitals.

Story Snapshot

An attorney told senators he won 72 hospital cases where ivermectin was given; 69 patients survived.
He said 212 families in 40 states sought court help over COVID-19 hospital care.
Major medical guidelines still advise against ivermectin for COVID-19 treatment.
Courts have increasingly deferred to hospitals on contested COVID-19 therapies.

What Lorigo Told Senators and Why It Resonates

Attorney Ralph Lorigo told Senator Ron Johnson’s roundtable that he represented 212 families across 40 states in disputes over hospital COVID care. He said he won 72 cases that forced hospitals to administer ivermectin. He stated that only three of those 72 patients died, implying 69 survived, a survival rate near 96 percent. His figures came in a public forum with named hosts, which makes the claim traceable, but the reports do not include case lists or audited records.

Lorigo’s statement taps a deep frustration on the right and left. Many families felt locked out of decisions while loved ones declined. They wanted options outside rigid protocols. Supporters see the court orders as proof that persistence saved lives. Critics see them as risky overrides of clinical judgment. Both sides share one worry: institutions seem more focused on rules and liability than on adapting quickly when patients are in trouble.

What the Evidence and Guidelines Say About Ivermectin

The Infectious Diseases Society of America recommends against ivermectin for ambulatory patients and suggests against it for hospitalized patients with COVID-19 outside clinical trials. A Cochrane review reported no evidence that ivermectin helps treat or prevent COVID-19, noting findings ranged from low- to high-certainty against benefit for outpatients. Several meta-analyses found no clear reduction in mortality, ventilation, or hospital time linked to ivermectin use in randomized trials.

These guideline positions underline a key gap in Lorigo’s account. His numbers are outcome tallies, not a controlled study. The reports do not show matching by age, severity, or timing, and do not separate ivermectin from other treatments. Without those details, the survival rate cannot be tied to ivermectin alone. That does not mean the patients did not improve. It means the mechanism of improvement is not proven by the figures provided.

How Courts Have Handled Treatment Fights Since 2021

Early in the pandemic, a few judges ordered hospitals to permit ivermectin for specific patients. Over time, appellate courts and state supreme courts trended toward deference to hospitals and treating teams. In Wisconsin, a high court case underscored the limits of compelling a hospital to administer a disputed drug. Legal analyses note that, in general, courts resist forcing clinicians to deliver care they do not judge appropriate.

These rulings reflect two concerns. First, judges fear ordering care that could expose clinicians to claims of malpractice. Second, courts lack the tools to weigh medical evidence in fast-moving crises. Families argue that delays cost lives. Hospitals argue that inconsistent orders create chaos. The result is a system that often leaves desperate families with few paths to try nonstandard options during critical windows of illness.

Why This Matters Beyond One Drug

This hearing spotlighted a bigger question: who decides at the bedside when time is short and evidence is mixed? Families want a voice. Doctors want room to practice without legal threats. Regulators want guardrails that protect patients. Congress can press for better transparency, faster evidence reviews, and clearer pathways for supervised, off-label use inside hospitals when families and doctors agree.

@UPMCpolicy @PAHealthDept @HealthAllegheny
Senate testimony: Families tell horror stories about COVID hospital deaths, mistreatment
One woman testified that her husband died after being put on a ventilator without consent, among other horrifying COVID hospital stories discussed…

— Gary Franzen (@Franz292Gary) September 29, 2026

Practical steps could build trust. Hospitals could publish protocols for considering compassionate use and document decisions. Courts could set narrow standards for emergency orders tied to clear medical oversight. Federal agencies could release timely summaries showing what worked, what failed, and why. These moves would not settle the ivermectin debate. But they would show the system serves patients first, not institutional comfort.